Tumor-derived exosomes promote carcinogenesis of murine oral squamous cell carcinoma.


Journal

Carcinogenesis
ISSN: 1460-2180
Titre abrégé: Carcinogenesis
Pays: England
ID NLM: 8008055

Informations de publication

Date de publication:
10 07 2020
Historique:
received: 26 04 2019
revised: 12 06 2019
accepted: 25 06 2019
pubmed: 28 6 2019
medline: 28 10 2020
entrez: 28 6 2019
Statut: ppublish

Résumé

Circulating tumor-derived exosomes (TEX) interact with a variety of cells in cancer-bearing hosts, leading to cellular reprogramming which promotes disease progression. To study TEX effects on the development of solid tumors, immunosuppressive exosomes carrying PD-L1 and FasL were isolated from supernatants of murine or human HNSCC cell lines. TEX were delivered (IV) to immunocompetent C57BL/6 mice bearing premalignant oral/esophageal lesions induced by the carcinogen, 4-nitroquinoline 1-oxide (4NQO). Progression of the premalignant oropharyngeal lesions to malignant tumors was monitored. A single TEX injection increased the number of developing tumors (6.2 versus 3.2 in control mice injected with phosphate-buffered saline; P < 0.0002) and overall tumor burden per mouse (P < 0.037). The numbers of CD4+ and CD8+ T lymphocytes infiltrating the developing tumors were coordinately reduced (P < 0.01) in mice injected with SCCVII-derived TEX relative to controls. Notably, TEX isolated from mouse or human tumors had similar effects on tumor development and immune cells. A single IV injection of TEX was sufficient to condition mice harboring premalignant OSCC lesions for accelerated tumor progression in concert with reduced immune cell migration to the tumor.

Identifiants

pubmed: 31245809
pii: 5524074
doi: 10.1093/carcin/bgz124
pmc: PMC7350555
doi:

Substances chimiques

B7-H1 Antigen 0
CD274 protein, human 0
Carcinogens 0
4-Nitroquinoline-1-oxide 56-57-5

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

625-633

Subventions

Organisme : NCI NIH HHS
ID : R01 CA168628
Pays : United States

Informations de copyright

© The Author(s) 2019. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Références

N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
Oncogene. 2019 Apr;38(15):2830-2843
pubmed: 30546089
Front Oncol. 2018 Oct 12;8:445
pubmed: 30370252
Cancer Sci. 2017 Sep;108(9):1803-1810
pubmed: 28667694
Nat Med. 2013 Nov;19(11):1423-37
pubmed: 24202395
Mol Cancer Res. 2018 Nov;16(11):1798-1808
pubmed: 30042174
Clin Cancer Res. 2006 Jul 1;12(13):3890-5
pubmed: 16818683
Cancer Res. 2011 Aug 1;71(15):5346-56
pubmed: 21670082
J Immunol. 2009 Sep 15;183(6):3720-30
pubmed: 19692638
Oncotarget. 2016 May 10;7(19):27033-43
pubmed: 27081032
Clin Cancer Res. 2017 Aug 15;23(16):4843-4854
pubmed: 28400428
Nat Cell Biol. 2015 Jun;17(6):816-26
pubmed: 25985394
J Vis Exp. 2018 May 6;(135):
pubmed: 29782011
Nat Cell Biol. 2008 Dec;10(12):1470-6
pubmed: 19011622
J Clin Oncol. 2015 Oct 10;33(29):3293-304
pubmed: 26351330
Future Oncol. 2017 Aug;13(18):1649-1663
pubmed: 28776423
J Immunol. 2005 Oct 15;175(8):5541-50
pubmed: 16210663
Proc Natl Acad Sci U S A. 2013 Apr 30;110(18):7312-7
pubmed: 23589885
Cancer Res. 2010 Dec 1;70(23):9621-30
pubmed: 21098712
Clin Exp Immunol. 2017 Sep;189(3):259-267
pubmed: 28369805
Clin Cancer Res. 2013 Feb 15;19(4):889-99
pubmed: 23363813
J Extracell Vesicles. 2016 Mar 24;5:29289
pubmed: 27018366
Sci Rep. 2017 Oct 31;7(1):14684
pubmed: 29089618
J Mol Histol. 2009 Jun;40(3):177-81
pubmed: 19685146
Semin Immunol. 2018 Feb;35:69-79
pubmed: 29289420
Adv Clin Chem. 2016;74:103-41
pubmed: 27117662
In Vivo. 2013 Jul-Aug;27(4):473-84
pubmed: 23812217
J Immunol Methods. 2012 May 31;379(1-2):1-14
pubmed: 22370428
Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):301-13
pubmed: 14734483
Nat Med. 2012 Jun;18(6):883-91
pubmed: 22635005
Cancer Res. 2015 Jun 1;75(11):2200-10
pubmed: 25832655
Clin Cancer Res. 2018 Jan 1;24(1):6-13
pubmed: 28751445
Future Oncol. 2017 Dec;13(28):2583-2592
pubmed: 29198150
J Immunol. 2013 Dec 1;191(11):5515-23
pubmed: 24184557

Auteurs

Beatrice M Razzo (BM)

Department of Medicine, NYU Langone Medical Center, New York, NY, USA.
Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

Nils Ludwig (N)

Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
UPMC Hillman Cancer Center, Pittsburgh, PA, USA.

Chang-Sook Hong (CS)

Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
UPMC Hillman Cancer Center, Pittsburgh, PA, USA.

Priyanka Sharma (P)

Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
UPMC Hillman Cancer Center, Pittsburgh, PA, USA.

Kellsye P Fabian (KP)

National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Ronald J Fecek (RJ)

Department of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

Walter J Storkus (WJ)

UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
Department of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

Theresa L Whiteside (TL)

Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Department of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH